Together, these genetic and epigenetic changes provide a multifaceted regulatory network that contributing to STX16 dysregulation in ccRCC, underscoring its potential as a therapeutic target for further investigation22. The gene discussed is STX16; the disease is nonpapillary renal cell carcinoma.